GGrantIndex
← Leaderboards

Vitalant

San Francisco, CA

Compare ↔
$107,962,839
Total funding
51
Grants

Funding over time

peak $13.9M · FY2006–25
$20M$15M$10M$5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$100,598,605 · 47
CDC$4,825,000 · 2
DOD$2,539,234 · 2

By mechanism

N01$52,087,460 · 5
R01$38,650,318 · 23
U01$4,525,000 · 1
R21$4,199,007 · 11
—$2,539,234 · 2
RC2$2,118,432 · 1

Investigators at Vitalant

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

1Kimberly Anne Thomas$375,3061 gr

Emerging Leaders

6–10 yrs in

1Shannon Kelly$367,4791 gr

All-Time

Most funded here, all years

1Graham Simmons$8,136,9517 gr2Rachael Peretz Jackman$4,091,8302 gr3Shibani Pati$3,716,0024 gr4Nareg Roubinian$1,924,0961 gr5Thelma Therezinha Goncalez$760,5951 gr6Marion Lanteri$469,6411 gr7Evan Martin Bloch$451,8681 gr8Kimberly Anne Thomas$375,3061 gr

Largest grants

Recipient Epidemiology and Donor Evaluation Study III (REDS-III) Internat'l Site$5,312,554
N01 · FY2013 · HL
REDS-IV-P - CENTER FOR TRANSFUSION LABORATORY STUDIES (CTLS) - SARS-CoV-2/COVID-19 STUDIES$4,748,941
N01 · FY2020 · HL
REDS-IV-P CENTER FOR TRANSFUSION LABORATORY STUDIES (CTLS) PHASE 2$4,595,382
N01 · FY2022 · HL
RFA-IP-24-046: Nationwide Cohort of Blood Donors to Estimate Burden of Respiratory Viruses and Immunologic Response$4,500,000
U01 · FY2024 · IP
Recipient Epidemiology and Donor Evaluation Study III (REDS-III) Central Lab$4,039,864
N01 · FY2013 · HL
REDS-IV-P - CENTER FOR TRANSFUSION LABORATORY STUDIES (CTLS), PHASE 1.$3,754,594
N01 · FY2019 · HL
Recipient Epidemiology and Donor Evaluation Study III (REDS-III) Central Lab$3,624,423
N01 · FY2014 · HL
REDS-IV-P BRAZIL HUB$2,702,179
N01 · FY2024 · HL
REDS-IV-P BRAZIL TRANSFUSION SAFETY RESEARCH PROGRAM PHASE 2$2,316,885
N01 · FY2021 · HL
REDS-IV-P BRAZIL PHASE 1$2,242,121
N01 · FY2019 · HL
REDS-IV-P CENTER FOR TRANSFUSION LABORATORY STUDIES$2,160,438
N01 · FY2024 · HL
REDS-IV-P DOMESTIC HUBS$2,104,121
N01 · FY2024 · HL
REDS-IV-P BRAZIL TRANSFUSION SAFETY RESEARCH PROGRAM PHASE 2$2,015,619
N01 · FY2022 · HL
RBC STORAGE EFFECT ON COAGULATION, MICROPARTICLES AND MICROCHIMERISM IN CRITICALLY ILL PATIENTS$1,990,900
· FY2011 · Department of the Army
Recipient Epidemiology and Donor Evaluation Study III (REDS-III) Central Lab$1,883,792
N01 · FY2011 · HL
REDS-IV-P DOMESTIC HUBS PHASE 2$1,766,199
N01 · FY2022 · HL
IGF::OT::IGF: Task Order TO No. HHSN26800003, titled Recipient Epidemiology and Donor Evaluation Study III REDS-III Central Laboratory - Characterization of blood transfusion-transmission of Zika viru$1,508,640
N01 · FY2016 · HL
REDS-IV-P DOMESTIC HUBS PHASE 2$1,415,306
N01 · FY2021 · HL
Mechanisms and clinical effects of microchimerism in transfused trauma patients$1,246,772
R01 · FY2007 · HL
Mechanisms and clinical effects of microchimerism in transfused trauma patients$1,235,637
R01 · FY2008 · HL